CD274 and ovarian cancer: There were no unexpected adverse events or additive toxicities seen in the MEDIOLA trial (NCT02734004), a phase 1/2 study examining the combination of olaparib and durvalumab (anti-PD-L1 antibody) in four different types of cancer: germline BRCA-mutated metastatic breast cancer, germline BRCA-mutated platinum-sensitive relapsed ovarian cancer, relapsed gastric cancer, and SCLC.